IMMUNITYBIO, INC.

IBRX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013
Operating Activities
Net Income $-96.4M $-120.8M $-236.9M $-6.2M $-2.0M
Depreciation & Amortization $5.6M $3.6M $1.5M $36.0K $4.0K
Depreciation $3.3M $1.0M $100.0K $36.0K
Amortization $2.3M $2.6M $1.3M $0
Stock-Based Compensation $37.0M $73.9M $211.2M $789.0K $884.0K
Net Cash from Operating Activities $-48.8M $-38.6M $-25.3M $-5.4M $-668.0K
Investing Activities
Capital Expenditures $34.8M $6.6M $2.2M $235.0K $3.0K
Business Acquisitions $0 $0 $1.8M $0
Net Cash from Investing Activities $99.6M $-113.7M
Financing Activities
Dividends Paid
Stock Repurchases $15.2M $15.8M $4.8M $0
Net Cash from Financing Activities $-35.0M $-15.6M
Net Change in Cash $15.8M $-167.8M $116.8M $58.8M $234.0K
Free Cash Flow $-83.6M $-45.2M $-27.5M $-5.7M $-671.0K
← Newer Page 2 of 2 Older →